tiprankstipranks
Trending News
More News >
Voyager Therapeutics (VYGR)
NASDAQ:VYGR
Advertisement

Voyager Therapeutics (VYGR) Stock Statistics & Valuation Metrics

Compare
1,125 Followers

Total Valuation

Voyager Therapeutics has a market cap or net worth of $170.16M. The enterprise value is $137.40M.
Market Cap$170.16M
Enterprise Value$137.40M

Share Statistics

Voyager Therapeutics has 55,336,445 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding55,336,445
Owned by Insiders2.29%
Owned by Institutions0.33%

Financial Efficiency

Voyager Therapeutics’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -24.01%.
Return on Equity (ROE)-0.22
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-24.01%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee465.12K
Profits Per Employee-377.92K
Employee Count172
Asset Turnover0.20
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio5.0
PS Ratio0.00
PB Ratio0.67
Price to Fair Value1.09
Price to FCF-1.51
Price to Operating Cash Flow-1.62
PEG Ratio0.07

Income Statement

In the last 12 months, Voyager Therapeutics had revenue of 80.00M and earned -65.00M in profits. Earnings per share was -1.13.
Revenue80.00M
Gross Profit80.00M
Operating Income-83.29M
Pretax Income-64.34M
Net Income-65.00M
EBITDA-78.56M
Earnings Per Share (EPS)-1.13

Cash Flow

In the last 12 months, operating cash flow was -111.97M and capital expenditures -2.04M, giving a free cash flow of -114.01M billion.
Operating Cash Flow-111.97M
Free Cash Flow-114.01M
Free Cash Flow per Share-2.06

Dividends & Yields

Voyager Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.36
52-Week Price Change-61.80%
50-Day Moving Average3.20
200-Day Moving Average4.72
Relative Strength Index (RSI)49.77
Average Volume (3m)720.74K

Important Dates

Voyager Therapeutics upcoming earnings date is Jul 31, 2025, TBA (Confirmed).
Last Earnings DateMay 6, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date

Financial Position

Voyager Therapeutics as a current ratio of 5.56, with Debt / Equity ratio of 15.40%
Current Ratio5.56
Quick Ratio5.56
Debt to Market Cap0.02
Net Debt to EBITDA0.35
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Voyager Therapeutics has paid 665.00K in taxes.
Income Tax665.00K
Effective Tax Rate-0.01

Enterprise Valuation

Voyager Therapeutics EV to EBITDA ratio is -3.81, with an EV/FCF ratio of -15.90.
EV to Sales3.74
EV to EBITDA-3.81
EV to Free Cash Flow-15.90
EV to Operating Cash Flow-19.55

Balance Sheet

Voyager Therapeutics has $236.02M in cash and marketable securities with $42.00M in debt, giving a net cash position of -$194.02M billion.
Cash & Marketable Securities$236.02M
Total Debt$42.00M
Net Cash-$194.02M
Net Cash Per Share-$3.51
Tangible Book Value Per Share$5.20

Margins

Gross margin is 48.55%, with operating margin of -104.11%, and net profit margin of -81.25%.
Gross Margin48.55%
Operating Margin-104.11%
Pretax Margin-80.42%
Net Profit Margin-81.25%
EBITDA Margin-98.19%
EBIT Margin-104.11%

Analyst Forecast

The average price target for Voyager Therapeutics is $15.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$15.00
Price Target Upside365.84% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast-43.75%
EPS Growth Forecast-8479.41%

Scores

Smart Score7
AI Score46
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis